



## Synta Announces Upcoming Oral Presentations on Hsp90-Inhibitor Drug Conjugate (HDC) Platform

February 18, 2014

LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 18, 2014-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the following HDC oral presentations are scheduled to take place:

**Meeting:** IASLC 14th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting in Santa Monica, California

**Title:** "Hsp90i-Drug Conjugates (HDC) New Platform"

**Date and Time:** Saturday, February 22, 2014, 10:35 – 10:40 am

**Presenter:** David Gerber, M.D., UT Southwestern, Dallas, Texas.

**Meeting:** Applied Pharmaceutical Chemistry 2014 in Cambridge, Massachusetts

**Title:** "Hsp90-Inhibitor Drug Conjugates (HDCs): An Innovative Drug Delivery Platform Technology"

**Date and Time:** Tuesday, March 4, 2014, 4:05 – 4:45 pm

**Presenter:** Weiwen Ying, Ph.D., Synta Pharmaceuticals Corp., Lexington, Massachusetts.

### About Hsp90-Inhibitor Drug Conjugates (HDCs)

HDCs are small-molecule drugs consisting of an Hsp90 inhibitor (targeting moiety) joined to an anti-cancer agent (payload) via a cleavable chemical linker optimized for controlled release of payload drug inside cancer cells. They exploit the preferential retention of Hsp90 inhibitors in tumors to selectively deliver anti-cancer payloads. HDCs represent a promising new therapeutic class with the potential to enhance the safety and efficacy of a wide range of small molecule anti-cancer drugs. Advantages relative to other tumor targeting strategies, such as antibody-drug conjugates (ADCs), include use of an intracellular target that is widely shared across cancer types, increased flexibility in the range of compatible payloads and linkers, and small molecule cellular uptake.

Synta has established proof of concept for HDC lead candidates in preclinical studies and has developed over 450 compounds, using a broad range of Hsp90 inhibitor moieties, cleavable linkers, and anti-cancer payloads. The latter include cytotoxic chemotherapeutics, kinase inhibitors, hormone therapies, immunomodulators, and epigenetic modifiers, creating the potential for next-generation compounds in each of these categories. Synta has filed worldwide patent applications that include comprehensive claims covering the HDC platform, compositions of matter, methods for identifying therapeutically effective compounds, and methods of use of such compounds against a wide range of diseases and conditions.

### About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities. For more information, please visit [www.syntapharma.com](http://www.syntapharma.com).

Source: Synta Pharmaceuticals Corp.

#### Investor Contact:

Synta Pharmaceuticals Corp.

Mindy Kohl, 781-541-7213

[mkohl@syntapharma.com](mailto:mkohl@syntapharma.com)

or

Argot Partners

Andrea Rabney, 212-600-1494

[andrea@argotpartners.com](mailto:andrea@argotpartners.com)

or

#### Media Contact:

Argot Partners

Eliza Schleifstein, 917-763-8106

[eliza@argotpartners.com](mailto:eliza@argotpartners.com)